Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"

Science. 2013 May 24;340(6135):924-f. doi: 10.1126/science.1235505.

Abstract

Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) reported that bexarotene rapidly reduces β-amyloid (Aβ) levels and plaque burden in two mouse models of Aβ deposition in Alzheimer's disease (AD). We now report that, although bexarotene reduces soluble Aβ40 levels in one of the mouse models, the drug has no impact on plaque burden in three strains that exhibit Aβ amyloidosis.

Publication types

  • Comment

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism*
  • Amyloid beta-Peptides / metabolism*
  • Animals
  • Apolipoproteins E / metabolism*
  • Brain / metabolism*
  • Male
  • Tetrahydronaphthalenes / pharmacology*
  • Tetrahydronaphthalenes / therapeutic use*

Substances

  • Amyloid beta-Peptides
  • Apolipoproteins E
  • Tetrahydronaphthalenes